Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: A substudy of ACTFAST

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Blanco Colio, Luis M ^a   Martín Ventura, Jose L ^a   De Teresa, Eduardo ^b   Farsang, Csaba ^c   Gaw, Allan ^d   Gensini, Gianfranco ^e   Leiter, Lawrence A ^f   Langer, Anatoly ^f,g   Martineau, Pierre ^h   Egido, Jesús ^a,i  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF FLORENCE   (Italy)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g CANADIAN HEART RESEARCH CENTRE   (Canada)

^h PFIZER INC   (United States)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

CD40 ligand; High cardiovascular risk; Inflammation; Statins; Thrombosis

Indexed keywords

ATORVASTATIN; CD40 ANTIGEN; CD40 LIGAND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TRIGLYCERIDES;

EID: 61549117198     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.514     Document Type: Conference Paper

References (12)

1. Mach F, Schönbeck U, Sukhova GK et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
2. André P, Nannizi-Alaimo L, Prasad SK et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
3. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
4. Garlichs CD, John S, Schmeisser A et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-2400.
5. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
6. Schonbeck U, Varo N, Libby P et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
7. Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
8. Semb AG, van Wissen S, Ueland T et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003; 4: 275-279.
9. Martineau P, Gaw A, de Teresa E et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) Study. Atherosclerosis 2007; 191: 135-146.
10. de Lemos JA, Zirlik A, Schöbeck U et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis. Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: 2192-2196.
11. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
12. Blanco-Colio LM, Martin-Ventura JL, de Teresa E et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007; 27: 168-174.